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The most used radiation therapy treatments 
based on treatment plans, in which the delinea-
tion of the target implicates the necessary definition 
of the margin around the clinical target volume 
(CTV). CTV with this specific, geometrical, buffer 
zone is defined as planning target volume (PTV). 
The size of the CTV-PTV margin depends on the 
internal movement of the tumour and the errors 
caused by the patient set-up and the dose delivery 
methods or specific dose distributions obtained 
during treatment. Correctly applied CTV-PTV 
margin should provide the delivery of the planned 
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dose to the CTV during the treatment [1–4]. Tak-
ing into account the accuracy of dose delivery - the 
size of the CTV-PTV margin depends on the ra-
diation therapy method selected in the treatment 
and on the image-guidance scenarios used during 
the treatment. Numerous investigators show that 
increasing the frequency of image guidance (IG) 
allows for smaller CTV-PTV margins [5–8], or that 
the magnitude of margins depends on the modality 
used for IG [9, 10].
The safety of the PTV-based treatments makes 
two main assumptions. First is that moderate 
changes in patient position or anatomy do not af-
fect the dose distribution and the second that the 
effects of the interplay between intra-fractional mo-
tion and dynamic fluence patterns are negligible 
[11]. Taking into account 5% as the acceptable do-
simetric accuracy between planned and delivered 
doses [12] a lot of studies confirmed that the safety 
PTV-based concept is suitable for photon radiation 
therapy [13–18]. Nevertheless, assuming the cor-
rectness of the dose delivery at the accelerator level, 
the distribution of the dose uncertainties could dif-
fer for different IG scenarios used during therapy. 
Therefore, the analysis of the plan robustness on the 
potential movement of the CTV and the deforma-
tions of the tissues caused from this movement is 
one of the crucial methods to obtain information 
about possible dose distributions during correctly 
performed radiation therapy.
There are two methods of robust plan analysis 
in the EclipseTM treatment planning system (TPS) 
(Varian Medical Systems, Palo Alto, CA, USA) that 
are available in the “Plan Uncertainty Parameters” 
dialogue box (PUP). First of them estimates how 
a change in patient set-up may affect the dose dis-
tribution, the other one forecasts the effect on the 
dose distribution if the target moves to other struc-
tures. While the first method simulates the dose 
distributions during the radiation therapy managed 
and controlled by classical IG, such as no action 
level (NAL) protocol, the other one tries to simu-
late the dose distributions obtained during daily IG 
procedures. Unfortunately, these scenarios do not 
include in the final budget of the dose distributions 
the effect caused by deformations of the soft tissues 
that are accompanying the change of position of 
the CTV.
This study aimed to present the solution, based 
mainly on Varian commercial products, for robust 
plan analysis, which includes the effects of the soft 
tissue deformations on the simulated dose distribu-
tions.
Materials and methods
Study was carried out on data of one patient 
with prostate-restricted cancer. The workflow of 
the developed procedure focused on three execu-
tive elements:
• in-house script for movement simulation of the 
CTV written in the Python programming lan-
guage; 
• the VelocityTM software (Varian Medical Systems, 
Palo Alto, CA, USA) for calculations of the de-
formation matrixes;
• the EclipseTM TPS for dose re-calculations and 
analysis. 
Figure 1 shows the general workflow of the au-
thors’ solution.
The contours, previously prepared by a radiation 
oncologist on original set of CT images, are used 
by an in-house script to create a set of artificial set 
of CT images — aCT(0,0,0). Our script used external 
(body), bones and CTV contours to create masks 
on CT images (Fig. 1. — In-house engine section). 
The pixel value assigned to the body was 0 HU, the 
pixel value assigned to the bone and CTV was 1000 
HU. In the next step, the in-house script simulates 
on aCT(0,0,0) all possible positions of the CTV and, 
finally, generates the group of aCT sets that differ in 
the position of the CTV in each direction (x, y and 
z) — aCT(x,y,z). The positions of the CTV are quanti-
fied by the pixel value (i.e. 0.98 mm) and are ranged 
in the CTV-PTV margin (10 mm buffer zone added 
spherically to CTV). 
All of the aCT sets are uploaded to the Velocity 
software where they are used to generate the defor-
mation matrixes and then to generate deformed CT 
sets (dCT) based on the original (planning) CT. The 
whole procedure was based on manual scripting in 
the VelocityTM software and included respectively:
• rigid registrations between aCT(0,0,0) and any oth-
er aCT(x,y,z);
• deformable registrations between aCT(0,0,0) and 
any other aCT(x,y,z) to generate deformation ma-
trixes (DM(x,y,z)) caused from different positions 
of CTV on aCT(0,0,0) and aCT(x,y,z);
• appling DM(x,y,z) to original set of CT images 
and generating deformed CT sets (dCT). The 
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same deformation matrixes were used to deform 
OARs contours. The deformable multipass al-
gorithm was used for the last two steps of the 
procedure [19]. 
The dCT sets are moved to the Eclipse software 
where they are linked with the original plan geom-
etry. For each dCT set, the doses were re-calculated. 
Two possible scenarios of IG procedures were con-
sidered [7, 20] when doses were re-calculated: 
• the first method: re-calculation is done for the 
original geometry. It simulates IG based on the 
bony anatomy (not included bone-independent 
movements of the CTV) — Figure 2A; 
• the second method: the isocentre from the origi-
nal plan geometry is moved according to the 
movement of the CTV (simulates IG based on 
soft tissues) — Figure 2B. 
Finally, the dose distributions for the CTV, rec-
tum and bladder for both scenarios were analysed 
used dose-volume histogram (DVH) metrics, in the 
same way as is possible for the currently developed 
tool in EclipseTM TPS (Fig. 2C).
Results
There is about 1700 possible deformations of the 
original set of CT images (dCT). This value was 
calculated by a script which moves a CTV mask in 
the step of one voxel in all directions and checks if it 
is still inside PTV. Number of possible positions of 
the CTV mask is dependent on the CTV-PTV mar-
gin. Twenty-six of them were selected as the most 
significant for the results. These were the most ex-
treme positions of the CTV inside the PTV in each 
direction (x, y, z) and their combinations (xy, yz, 
xz, xyz). The dCT sets, obtained in this way, were 
exported to EclipseTM TPS where the doses were 
re-calculated for them according to two proposed 
scenarios. Additionally, the original treatment 
plan has been simulated by the Varian’s formula 
implemented in the System. Figure 3 shows the 
uncertainty of the dose distribution in CTV, blad-
der and rectum for two scenarios of IG, calculated 
by authors’ solution and by the tool commercially 
implemented in EclipseTM TPS.
Discussion
The term “robustness” in the light of the radio-
therapeutic plans is considered in two ways. First 
of them is a robust plan optimisation — the set of 
procedures that allows minimising potential un-
certainties of the dose distribution during the plan 
preparation. During the robust optimisation, a lot 
Figure 1. General workflow of the authors’ solution. act — artificial set of ct images; dct — deformed set of ct images; 
1st method — re-calculation is done for the original geometry (simulation of iG based on the bony anatomy); 2nd method 
— the isocentre from original plan geometry is moved according to the movement of the ctV (simulation of iG based on soft 
tissues)
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Figure 3. the uncertainty of the dose distribution in ctV, bladder and rectum for two scenarios of iG, calculated by authors’ 
solution (A, b) and the Varian’s formula implemented in the eclipsetM tPS (c) 
a
B c
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of scenarios were considered. Each scenario rep-
resents a possible treatment course and should in-
clude a specification of all the errors that are needed 
to calculate the final dose distribution [21]. The sec-
ond way is a robust plan analysis — the analysis of 
the potential uncertainties of dose distribution for 
a single plan prepared in a conventional way (i.e., 
patient in a fixed nominal position and considering 
CTV-PTV margins). In other words, the intention 
of a robust optimisation is a reduction of potential 
uncertainties of doses on the level of plan prepa-
ration and, then, proper irradiation. In contrast, 
a robust plan analysis answers the question of how 
accurate is the treatment based on the plan created 
conventionally. This study focuses on a robust plan 
analysis.
EclipseTM TPS has a tool for calculation of the 
dose uncertainty for conventionally prepared treat-
ment plans. The procedure of uncertainty simula-
tion in this tool is quite simplified and based on 
moving the whole patient’s body around the iso-
centre of the treatment (Fig. 2C). The scenarios 
of available simulations there do not include the 
changes of dose distribution caused by deforma-
tions of the soft tissues that are accompanying the 
shift in the position of the CTV. Moreover, they 
do not precisely simulate the different scenarios of 
IG that have an impact on the difference in doses. 
When daily is IG based on the bony anatomy, the 
isocentre of the treatment is fixed in the same geo-
metrical place for each fraction. Potential differenc-
es in the fraction doses in the tumour (CTV) as well 
as in organs at risk (OARs) are caused by the move-
ment of the CTV and different filling of OARs (i.e. 
bladder, rectum) during fractions (Fig. 2A). In the 
case of daily IG based on soft tissues, the isocentre 
of the treatment depends on the current position of 
the CTV before the fraction dose delivery. While 
the impact of OARs deformation on the doses is 
similar, the inter-fraction tracking of CTV position 
reduces effectively the dose differences in the CTV 
caused by different positions of the CTV. Neverthe-
less, the different distance between the skin and the 
isocentre may cause a difference in doses (Fig. 2B). 
The observations listed above motivated us to 
develop an in-house solution that enabled more 
precise simulations of dose uncertainties. In our so-
lution, as in the Varian’s tool, the dose uncertainty 
analysis is based on the information gathered on 
the DVH. The DVHs from our method are more 
informative than the DVH from commercially im-
plemented tools. For the first scenario (IG based on 
bony anatomy, Fig. 3A), the highest impact on dose 
uncertainty has boundary positions of the CTV to 
the CTV-PTV margin and relocation of the CTV 
that causes changes of OARs volumes that receive 
high doses. For the second scenario (IG based on 
soft tissues, Fig. 3B), dose uncertainty is affected to 
the highest degree by the CTV position in relation 
to the whole body and relocation of the isocentre 
that causes changes in the general dose distribution 
(visible for OARs volume receiving low and inter-
mediate doses). The current version of our proce-
dure is limited to the solid (nondeformed) CTVs.
Except the in-house engine used to generate aCT 
sets with different position of the CTV, the tools 
(i.e. VelocityTM and EclipseTM) used in our simula-
tions are developed by the Varian Medical Systems. 
They are being used commercially in a lot of centres 
based on the Varian’s radiotherapeutic line. Moreo-
ver, it is possible to automatise the procedures car-
ried out in VelocityTM and EclipseTM by scripting 
language implemented in these programs. Due to 
this fact, it is easy to implement this solution in 
centres based on Varian’s line.
conclusion
The proposed method of simulating the uncer-
tainty of dose distributions enables a more accurate 
analysis of the treatment plan robustness than the 
method currently implemented in EclipseTM TPS.
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